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Preclinical stages in the drug discovery process require a multitude of biochemical and genetic assays in
order to characterize the effects of drug candidates on cellular systems andmodel organisms. Early attempts
to apply unbiased proteomic techniques to the identification of protein targets and off-targets as well as to
elucidate the mode of action of candidate drug molecules suffered from a striking discrepancy between
scientific expectations and what the technology was able to deliver at the time. Dramatic technological
improvements in mass spectrometry-based proteomic and chemoproteomic strategies have radically
changed this situation. This review, therefore, highlights proteomic approaches suitable for preclinical
drug discovery illustrated by recent success stories.Introduction
Themajority of small molecule drugs and biologics act on protein
targets. These proteins do not act in isolation but are embedded
in cellular pathways and networks and are thus tightly intercon-
nected both physically and functionally with many other proteins
and cellular components. In addition, the several hundred
different cell types that make up the organs of a human being
constitute different physical and functional contexts in which
proteins exist and on which drugs may therefore act with desir-
able or undesirable consequences. Given this complexity, it
seems natural to apply proteomics in the drug discovery process
in order to understand the effects of drug candidates on their
protein targets and shed light on the cellular mechanisms result-
ing in the observed phenotype. The success of proteomics in
basic biology research has been striking. However, similar to
the early genomic promises, expectations toward proteomics
in drug discovery were often higher than what the technology
was able to deliver at the time. Early applications in this area
were largely confined to measuring global effects of drugs on
protein expression with little direct information on the mecha-
nisms by which the observed effects were generated. At the
same time, the technology was underdeveloped because it
suffered from limited analytical depth and quantification capa-
bility. Over the last 15 years, proteomic technology has made
dramatic progress in several areas (Mallick and Kuster, 2010).
The introduction of separation and analytical strategies including
multidimensional liquid chromatography of peptides coupled to
high-performance tandem mass spectrometry (Graumann et al.,
2008; Olsen et al., 2005, 2009; Washburn et al., 2001) led to
a dramatic increase in the depth of sampling of a given pro-
teome. Furthermore, a robust quantitative dimension was added
to mass spectrometric measurements by stable isotope labeling
(Ong et al., 2002; Ross et al., 2004; Thompson et al., 2003) or so-
called label-free techniques (Bantscheff et al., 2007b). In
addition, tremendous improvements have been made in the
large-scale analysis of low molecular weight posttranslational72 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rmodifications (PTMs). Examples include phosphorylation (Beau-
soleil et al., 2004; Olsen et al., 2006) and acetylation (Choudhary
et al., 2009), which both play a crucial role in regulation of protein
activity, stability, as well as protein interactions.
The ability of state-of-the-art proteomics to measure the
changes of proteins and their various isoforms quantitatively to
a depth of 5–10,000 proteins and across 4–6 logs of dynamic
range in abundance makes it, in our eyes, an important tool at
various stages during small molecule drug discovery (Beck
et al., 2011; Nagaraj et al., 2011). Currently, drug discovery
efforts typically follow one of two strategies that differ in the
way they lead to compound selection and optimization (Figure 1).
Target-based approaches start with the selection of a protein
target based on its presumed or validated role in the relevant
disease. Biochemical or biophysical assays, typically using puri-
fied protein, are developed to monitor modulation of target
activity and to identify hits in high-throughput screens (HTSs)
using large libraries of small molecules. After hit validation,
lead compounds are selected and further optimized with regard
to potency, selectivity, pharmacodynamic and pharmacokinetic
properties, and tested for in vivo efficacy in the respective
disease model. Recently, phenotypic screening regimen in
general and genetically designed pathway-centric approaches
in particular have (re)gained popularity in drug discovery
because the conditions of such screens resemble more closely
the physiological situation compared to assaying a target in
isolation (Fishman and Porter, 2005). Here, a cellular assay is
used for screening a small molecule library using a cellular
response readout such as cytokine release, cell death, or
pathway activity (e.g., the phosphorylation status of a signaling
protein or reporter gene activity). The targets of hits generated
in this way are initially unknown. Therefore, a phenotypic screen
is typically followed by target deconvolution (for a definition see
below and Box 1), target validation, and elucidation of the mode
of action by which the small molecule hit exerts its pharmacolog-
ical effect.ights reserved
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Figure 1. Applications of Proteomics at
Different Stages in the Drug Discovery
Process
Overall goals of these applications are similar for
both traditional, target-based drug discovery
(upper panel) and phenotypic, chemical genetics-
based drug discovery (lower panel), but there are
differences in when they are applied during the
process. ID, identification.
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teomics enables a multitude of investigations relevant to the
different steps and addressing different questions in the process
(Figures 1 and 2). These applications can be roughly grouped
into (1) those characterizing direct or indirect drug-target interac-
tions for target deconvolution and selectivity profiling, (2) those
aimed at elucidating the mechanism of action (MoA) by which
a drug exerts its pharmacological effect, target characterization,
and validation, and (3) those aimed at the identification of
biomarkers that can be used for monitoring the effect of target
modulation in an in vivo setting. Due to space constraints, we
focus in this review on the contributions of mass spectrometry-
based proteomics to the preclinical stages of small molecule
drug discovery. For clinical applications of proteomics including
biomarker discovery, we refer the interested reader to a number
of reviews that have been published on the topic (Rifai et al.,
2006; Ioannidis, 2011).
Characterization of Drug-Protein Interactions
Target Deconvolution and Selectivity Profiling
We use the term target deconvolution to describe proteomic
experiments aiming at identifying the full spectrum of (protein)
targets associated with a bioactive molecule and the cellular
phenotype it induces. This level of compound characterization
has not traditionally been done in drug discovery in part because
it was not technically possible. The value of this information is,
however, quite obvious. Small molecule drugs should be ex-
pected to bind to more than one protein, and there is evidence
that polypharmacology is indeed more often the case than
not. In a physiological context, binding to or activity modulation
of more than one protein may have desirable or undesirable
consequences. Knowledge about the spectrum of proteins in-
teracting with a small molecule could inform early on about
drug safety (by the identification of potential toxicity targets),
help in the decision making along the development process of
a small molecule (e.g., which lead series to prioritize), and
even lead to the repositioning of existing drugs (e.g., by the iden-
tification of additional targets). It may, therefore, be argued thatChemistry & Biology 19, January 27, 201detailed target deconvolution ought to be
part of every drug discovery project.
For target-based drug discovery the
protein target is nominated before
screening (e.g., based on a known mech-
anistic role in disease or on the correlation
of factors such as gene copy number,
mutational status, or levels of RNA or
protein with disease status). Because
the target proteins are usually expressed
in recombinant form and screenedagainst a large/focused library of test compounds using their
enzymatic activities, target deconvolution primarily means es-
tablishing target selectivity (i.e., which other proteins of the
same or different protein classes are bound/inhibited/activated
by the small molecule?). In part this can be achieved using
panels of enzyme assays (e.g., for kinases, proteases, GPCRs,
ion channels, P450 enzymes, etc.), but these assays cannot
identify unexpected drug-target interactions. Target deconvolu-
tion in the context of phenotypic screens is quite different. These
screens are unbiased in the sense that they do not focus on tradi-
tional target classes and assay types. Instead, the screens focus
on the desired cellular phenotype that, mechanistically, may be
due to modulation of any protein within the probed signaling
pathways. In a nutshell, the protein target responsible for the
observed effect is unknown, which, not surprisingly, complicates
or even precludes the chemical optimization of screening hits
(Terstappen et al., 2007). Target deconvolution in this context,
therefore, primarily needs to establish the efficacy target. In
addition to the enzyme panels mentioned above, a variety of
unbiased techniques can be employed for this purpose including
in silico target prediction and genetic and transcriptional profiling
(e.g., haploinsufficiency profiling; Giaever et al., 1999, 2004; for
a recent review see Cong et al., 2011). Alternatively, affinity-
based techniques can be employed as a strategy for measuring
drug-target interactions directly. Commonly used methods here
include yeast or mammalian three-hybrid systems, phage
display, and chemoproteomics (Rix and Superti-Furga, 2009;
Terstappen et al., 2007). Chemoproteomic target deconvolution
is based on classical drug affinity chromatography pioneered by
Schreiber and colleagues in their seminal work on the identifica-
tion of molecular targets of immunosuppressants (Brown et al.,
1994; Harding et al., 1989) and inhibitors of histone deacetylation
(Taunton et al., 1996). Nowadays, the affinity purification is typi-
cally followed by mass spectrometry for protein identification
and quantification. The main applications of chemoproteomic
target deconvolution can be grouped into two categories: (1)
drug-centric profiling, and (2) binding mode-centric profiling
(selectivity profiling).2 ª2012 Elsevier Ltd All rights reserved 73
Box 1. Glossary of Terms
ADME Appropriate properties in absorption, distribution, metabolism, and excretion (ADME) are required tomake
a bioactive compound an effective drug.
Drug development Preclinical and clinical studies required to establish drug safety and efficacy.
Drug discovery Process by which drugs are designed or discovered.
Drug target deconvolution Process of identifying target molecules of bioactive (small) molecules, e.g., for compounds active in
a phenotypic screen.
Mechanism of action (MoA) Mechanism by which a drug exerts its pharmacological effect.
Off-target Additional targets whose modulation is not or not necessarily related to the desired phenotypic response.
Pharmacodynamic biomarker Marker of a pharmacological response monitored in dose optimization studies, e.g., substrate
phosphorylation state of kinase targets.
Pharmacodynamics Study of the concentration dependence of biochemical or physiological effects of a drug on an organism.
Pharmacokinetics Study of ADMEproperties of a drug as a function of time, in particular the rate at which a drug action begins
and the duration of the effect.
Phenotypic drug discovery Drug discovery based on phenotypic screens inwhich libraries of small molecules are tested for their ability
to exert a desired phenotypic response in a cellular assay, such as cytokine release, cell death, or
transcriptional activity of engineered reporter genes.
Target Molecular entity expressed in a cell or organism whose structure or function is directly modulated by drug
binding, thus leading to a desired phenotypic/therapeutic response.
Target-based drug discovery Design of therapeutics specifically modulating the function of a distinct validated target.
Target validation Process aiming to demonstrate that modulation of the target will have the desired therapeutic effect
(in vivo).
Therapeutic index Comparison of the drug concentration required to achieve the desired therapeutic effect to the drug
concentration that causes toxicity or death.
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In this approach the bioactive molecule of interest is chemically
conjugated to a suitable affinity moiety (e.g., biotin) or immobi-
lized directly on a resin such as Sepharose beads. In both cases,
chemical synthesis of a suitable functionalized analog of the
compound will generally be required (typically bearing an amine,
carboxyl, hydroxyl, or sulfhydryl group). Detailed information on
the structure activity relationship (SAR) of a compound is neces-
sary to ensure that the functionalized molecule retains similar
target binding and biological activity properties. The resulting
affinity probe is then incubated with cell extracts, and bound
proteins are identified using mass spectrometry (Bantscheff
et al., 2009; Lolli et al., 2003; Oda et al., 2003; Rix and Superti-
Furga, 2009). Successful applications of this approach cover
a diverse set of target classes such as protein kinases (Bant-
scheff et al., 2007a; Brehmer et al., 2004, 2005; Daub et al.,
2008; Godl et al., 2005; Li et al., 2010; Rix et al., 2007), proteins
binding to ATP/ADP (Graves et al., 2002), phosphatidylinositols
(Gharbi et al., 2007; Krugmann et al., 2002), cyclic nucleotides
(Hanke et al., 2011; Scholten et al., 2006), histone deacetylases
(HDACs) (Bantscheff et al., 2011), and tankyrases (Huang et al.,
2009). The same idea is, in principle, also applicable to protein
therapeutics and other biologics (Geuijen et al., 2005). The inter-
pretation of chemoproteomic experiments is often complicated
by the fact that dozens to hundreds of proteins are identified in
a typical experiment. Hence, additional evidence is required to
distinguish genuine high-affinity target proteins from low-affinity
but highly abundant proteins. For example, albumin and hemo-
globin are known to have low affinity for a range of small mole-
cules, and many NADH/NADPH binding proteins also bind to74 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rimmobilized ATP mimetics (Brehmer et al., 2004, 2005; Godl
et al., 2005; Remsing Rix et al., 2009; Rix et al., 2007). In addition,
proteins might bind to the resin itself or to additional groups
introduced to a compound for probe generation (e.g., linkers,
reactive groups, biotin, etc.). Such proteins are detected
frequently in independent experiments using different probe
matrices and are often simply neglected in the further analysis
(Trinkle-Mulcahy et al., 2008). A more elaborate strategy to avoid
false-positive target deconvolution results is to design active and
inactive analogs of the affinity probe (Oda et al., 2003). Experi-
ments with both matrices are then performed in parallel, and
candidate target proteins can be short-listed on the basis of
differential purification. However, inactive analogs of candidate
molecules are often not available, and synthesizing additional
such probes is laborious. Competition binding experiments
provide a simple but very efficient alternative to address false-
positive target deconvolution. Here, the affinity probe is incu-
bated with the cell extract in the presence or absence of the orig-
inal (i.e., unmodified) bioactive compound. Genuine target
proteins show significantly reduced binding to the resin in this
experiment compared to vehicle control, whereas nonspecific
binders do not. Technically, the reliability of the results of such
competition binding assays hinges on a number of parameters.
The abundance of the target protein and its affinity to the small
molecule are the two most important biochemical determinants
of the observable competition. In particular the rate at which
proteins dissociate from the immobilized compound (koff) deter-
mines how much of a protein can be recovered given the time
required to perform the affinity purification. For a high-abun-
dance target, interactions with dissociation constant (KD) valuesights reserved
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et al., 2009). More generally though, de novo target deconvolu-
tion experiments typically require compounds with cellular
potencies in the submicromolar range because most signaling
proteins tend to be of rather low abundance. The precision and
accuracy of the mass spectrometric protein quantification are
other important factors in these experiments. Here, the use of
stable isotope labeling such as SILAC (Ong et al., 2009) or
isobaric labeling tags (Bantscheff et al., 2007a, 2011; Borawski
et al., 2009; Burgett et al., 2011; Huang et al., 2009) has improved
the data quality significantly in recent years and now enables
measurements within 20% CV (coefficient of variation).
As an alternative to the use of reversible binders, reactive
probes can be employed that covalently attach to a target
protein active site (commonly known as ‘‘activity-based protein
profiling’’ [ABPP], reviewed by Cravatt and coworkers in this
issue of Chemistry & Biology) (Cravatt et al., 2008; Nomura
et al., 2010; Sadaghiani et al., 2007). Similarly to the aforemen-
tioned methods, the bioactive molecule of interested needs to
be chemically modified to enable the reaction of the active site
probe with suitable amino acid residues within or close to the
enzyme catalytic site. This is attractive because the covalent
nature of the binding has the potential to overcome the affinity
issues often encountered with reversible binders. In addition,
chemical probes for particular target classes can be designed.
However, significant chemical effort is required in defining
a chemical probe that is sufficiently similar to the bioactive mole-
cule under investigation. This is likely a main reason why reactive
probes have been primarily reported for binding mode-centric
profiling rather than compound-centric chemoproteomics (see
section below). A variation on this theme that aims at streamlin-
ing probe development employs trifunctional probe designs that
consist of (i) a selectivity group that can reversibly interact with
a particular target protein or target class, (ii) a common reactive
group that stabilizes the interaction, and (iii) a common sorting
function (e.g., biotin) that allows purification of the drug-target
complex (Ko¨ster et al., 2007). Despite synthetic challenges,
reactive probes for photolabeling (using, for example, diazirine
or benzophenone moieties) are of particular interest for target
proteins that are less amenable to simple affinity enrichment
such as G protein-coupled receptors and other integral
membrane proteins (Dubinsky et al., 2011; Tantama et al., 2008).
For all affinity/activity-based methods described thus far,
chemical synthesis of suitably functionalized analogs is the
rate-limiting step. To overcome this, recent reports suggest
that structural changes in target proteins induced by binding of
the free (unmodified) bioactive compound may be directly inter-
rogated by mass spectrometry. The method of ‘‘drug affinity
responsive target stability’’ (DARTS) introduced by Lomenick
et al. (2009) takes advantage of a local or global reduction in
the protease susceptibility of a target protein upon drug binding.
For example, thermolysin digestion of resveratrol-treated yeast
and human cell lysates revealed stabilization of wild-type
eIF4A, but not the A64Q eIF4A mutant protein, suggesting that
the protein translation machinery may be a molecular target of
resveratrol in life span extension. Another method in this group
is ‘‘Stability of Proteins from Rates of Oxidation’’ (SPROX), which
measures the thermodynamic stability of proteins and protein-
ligand complexes by measuring hydrogen peroxide-inducedChemistry & Biolprotein oxidation as a function of denaturant concentration
(e.g., guanidinium hydrochloride) (West et al., 2008) or heat dena-
turation (West et al., 2010a). Measurements in the absence or
presence of ligand thus enable evaluation of protein-ligand affin-
ities. Thepotential of suchmethodshasbeenhighlighted recently
by the simultaneous assaying of the protein-folding and ligand-
binding properties of 327 proteins in a yeast cell lysate using
the immunosuppressive drug cyclosporin A (West et al., 2010b).
The impact of drug-centric chemoproteomic profiling for
target deconvolution has been rapidly increasing lately. For
example Fleischer et al. used affinity-based proteomics to delin-
eate nicotinamide phosphoribosyltransferase as the target of the
potent and selective cytotoxic agent CB30865. This enzyme is
a member of the NAD biosynthetic pathway that helps cancer
cells to sustain their increased energy metabolism (Fleischer
et al., 2010). Following a HTS using a Wnt-responsive reporter
assay, Huang et al. used chemoproteomics to identify tank-
yrases as the targets of the small molecule hit XAV939. This
experiment validated tankyrases as tractable targets in the Wnt
signaling pathway, which plays an important role in the develop-
ment of colorectal cancer (Huang et al., 2009). Raj and
colleagues used a SILAC-based chemoproteomic approach to
identify several enzymes of the cellular stress response to reac-
tive oxygen species (ROS), including glutathione S-transferase
pi 1 (GSTP1) and carbonyl reductase 1 (CBR1), as interactors
of the natural product piperlongumine. In contrast to other
compounds increasing ROS levels such as paclitaxel, the
authors found that the increase in ROS levels and apoptotic
cell death caused by piperlongumine is restricted to cancer cells,
whereas no effect was observed in normal cells. Biochemical
and cellular data indicate that this effect is at least partially medi-
ated by the putative targets GSTP1 and CBR1. These results
suggest an approach to cancer therapy exploiting the increased
dependence of cancer cells on the ROS stress response
pathway (Raj et al., 2011). Nicodeme et al. performed cell-based
screening for inhibitors of Apolipoprotein AI production, and pro-
teomic profiling of hit compounds led to the unexpected
discovery of bromodomain proteins as tractable targets for the
modulation of apolipoprotein transcription. The inhibitors exhibit
a MoA by blocking the protein-protein interaction formed
between acetylated histones and the bromodomains of BET
family proteins, which were not previously regarded as tractable
targets (Nicodeme et al., 2010). Bradner and coworkers recently
demonstrated that the small molecule compound JQ1 displaces
BET proteins from the chromatin and that this compound is effi-
cacious in patient-derived xenograft models of squamous carci-
noma carrying a recurrent translocation of BRD4 (Filippakopou-
los et al., 2010). Dawson et al. applied a multitier proteomic
strategy to characterize BET-dependent histone binding of
various protein complexes including the super elongation
complex (SEC) and the polymerase-associated factor complex.
These data provided the basis for therapeutic intervention in
MLL-fusion leukemia via the displacement of the BET family of
proteins from chromatin, and in vivo studies with the lead
compound I-BET151 demonstrated a marked survival benefit
in two distinct mouse models of murine MLL-AF9 and human
MLL-AF4 leukemia (Dawson et al., 2011).
Taken together, these recent success stories demonstrate
that chemoproteomic approaches not only enable theogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 75
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Figure 2. Schematic Representations of Exemplary Proteomic Workflows Addressing Different Questions Related to Drug Discovery
In all cases, relative protein quantification is achieved by quantitative mass spectrometry using either stable isotope labeling or label-free methods.
(A) Global protein profiling and its variant PTM profiling aim at the comprehensive analysis of protein abundance and levels of PTMs of proteins in a drug-
treated sample versus a control cell (tissue) sample or test animal. After treatment, proteins are typically extracted from the sample, digested into peptides, and
analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). For PTM profiling, a PTM-specific enrichment step is typically
included.
(B) Drug affinity profiling for target deconvolution using Drug-centric chemoproteomic profiling based on an immobilized bioactive molecule. The specificity of
protein binding to the drug matrix is probed by competition with the free drug. The abundance of target proteins of the drug (green) is reduced in experiments
performed in the presence of excess concentrations of the free drug.
(C) Selectivity profiling using Binding mode-centric chemoproteomic profiling, here exemplified by a reactive probe-based strategy. Probes are designed to
enable binding and subsequent purification of a whole class of protein targets (e.g., kinases) from cell extracts. In a second step, probes and bound targets are
76 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved
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same time, also provide insight into regulatory mechanisms de-
pending on protein-protein interaction rather than single
proteins. This extends the classical target definition to protein
complexes. Indeed, selective targeting of protein complexes
was recently demonstrated in a chemoproteomic study on
HDAC inhibitors (Bantscheff et al., 2011). Here, a competition
binding approach was applied to the profiling of inhibitors
binding to native megadalton HDAC complexes in cell extracts.
Unexpected differences in inhibitor binding to class I HDAC
complexes were observed. Despite the fact that these
complexes are formed around the same catalytic subunits, ben-
zamide inhibitors did not bind to the SIN3 repressor complex, but
both benzamide and hydroxamate-type compounds efficiently
inhibited the NuRD and Co-Rest complexes.
It should be noted that, strictly speaking, chemoproteomic
experiments generate target hypotheses, in particular when
using noncovalent chemical probes. These putative targets
may often be ranked by affinity or correlation with potency within
an SAR series of molecules of the same chemical scaffold.
However, formal proof for direct compound-protein binding still
needs to be provided, for example using purified protein and
biophysical methods such as surface plasmon resonance or
isothermal titration calorimetry. Moreover, direct interaction still
does not necessarily prove involvement of a target in the desired
phenotype. It may also represent an undesired (or no) effect or
indicate involvement of this protein, e.g., in compound metabo-
lism. In order to establish a functional relationship, bioinformatic
analysis for a connection of the putative target to the observed
cellular response is often used as a first-pass approach to prior-
itize a list of potential protein targets for follow-up. For many (but
by far not all) enzymes, biochemical assays with purified protein
can be established to verify modulation of activity by the
compound. The most important step is, however, the functional
validation in vivo. This typically includes experiments that aim to
phenocopy the compound treatment by modulating the protein
genetically (e.g., by RNA interference or cDNA overexpression)
and by using known inhibitors (if available) of the putative target.
If genetic and pharmacological intervention leads to the same
phenotype, the target hypothesis is generally valid. It should,
however, be noted that phenotypic screens often identify
compounds that work via multiple targets (related or not), which
all need to be targeted together to achieve the desired effect. The
downstream validation experiments can, therefore, easily lead to
false-negative results. For example, co-knockdown of both the
TNKS1 and TNKS2 enzymes was required to recapitulate the
effect of the tankyrase inhibitor XAV939 on Wnt signaling
mentioned above (Huang et al., 2009).
Binding Mode-Centric Profiling (Selectivity Profiling)
In contrast to completely unbiased drug-centric chemoproteo-
mic profiling (see above section), binding mode-centric profiling
focuses on the binding/activity of small molecules againstpurified using affinity chromatography before trypsin digestion and LC-MS/MS an
performed in the presence or absence of excess free drug (green protein is a dr
(D) Protein-protein interaction profiling, here exemplified by an antibody-based
against the protein target (red) or an isotype-matched unspecific IgG preparat
endogenous functional interactors of the target protein (blue) are enriched in exp
ground). In some cases, drug binding affects protein complex composition (midd
protein interaction site or via induced conformational changes.
Chemistry & Biolproteins of a particular protein target class to establish the selec-
tivity of a compound. Like for the drug-centric approaches,
current techniques typically comprise competition binding
assays based on affinity proteomics using noncovalent (Bant-
scheff et al., 2009; Hall, 2006; Rix and Superti-Furga, 2009) or
covalent chemical probes (Cravatt et al., 2008; Sadaghiani
et al., 2007; Nomura et al., 2010) and quantitative mass spec-
trometry. Themain differences to the drug-centric mode of oper-
ation are that (1) the proteins that constitute the target class need
to contain a molecularly conserved and druggable binding site
(such as a cofactor binding site), and (2) the chemical probe em-
ployed ideally binds to all members of the target class. For selec-
tivity assessment the compound of interest is typically used as
a competitor over a range of concentrations in a lysate (or on
cells) of a disease-relevant cell line or tissue. The affinity of the
compound to all members of the target class is determined by
quantifying the (reduced) amount of proteins captured by the
affinity matrix or activity probe. More specifically, inhibition of
binding curves is obtained from which apparent KD values can
be calculated (Patricelli et al., 2011; Bantscheff et al., 2011;
Sharma et al., 2009). This is a very powerful approach because
proteins are assayed under close-to physiological conditions
(e.g., use of relevant cell line or tissue; proteins at endogenous
expression levels and with natural modification status). In addi-
tion the multiplexing capability of mass spectrometry for protein
identification and quantification provides ranked affinities of
a compound against all members of the target class in one
experiment.
For protein kinases the conserved ATP-binding site has been
used by several groups to generate nonselective ATP-competi-
tive affinity matrices that provide selectivity assessments for
up to 150 kinase targets in a single experiment (Bantscheff
et al., 2007a; Sharma et al., 2009; Schirle et al., 2012). Such
matrices have been successfully applied to the selectivity
profiling of clinical BCR-ABL inhibitors in the chronic myeloid
leukemia cell line K562 (Bantscheff et al., 2007a), EGFR inhibi-
tors in HeLa cells (Sharma et al., 2009), and a range of 13
investigational and clinical multi-kinase inhibitors in patient-
derived primary chronic lymphocytic leukemia cells (Kruse
et al., 2011). Immobilized kinase inhibitors have also been used
to identify targets in head and neck cancer by analyzing the
kinase complement across 34 squamous cell carcinoma lines
established from patients (Wu et al., 2011). Other examples
for a pan-target family affinity matrix are the hydroxamates sub-
eroylanilide hydroxamic acid (SAHA) and givinostat, used for
selectivity profiling of class I and IIb HDACs in the context of
different physiological protein complexes (Bantscheff et al.,
2011).
As mentioned earlier, ABPP typically uses active site-reactive
chemical probes to probe for selectivity across a given enzyme
family (reviewed in Cravatt et al., 2008 and in this issue). These
probes react either in a truly activity-based mode with thealysis. Drug selectivity within the probed target class is revealed by experiments
ug target, whereas red and blue proteins are not).
strategy. Cell extracts are incubated with an immobilized antibody directed
ion (‘‘mock IP,’’ light-blue antibody, right panel). Only the target protein and
eriments with bait-directed antibodies versus mock IPs (green protein, back-
le panel shows loss of the blue protein) either by direct binding to the protein-
ogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 77
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binding site. Examples for the former include the fluorophosph-
onate probes targeting serine hydrolases (SHs) (Liu et al., 1999)
and (acyloxy)methyl ketone probes targeting cysteine proteases
(Krantz et al., 1991). Examples for the latter are the acylphos-
phate probe for kinases that reacts with a conserved lysine
residue (Patricelli et al., 2007) and the photoreactive SAHA-
based probe for HDACs (Salisbury and Cravatt, 2007). In addi-
tion to the examples above, probes have also been developed
for a variety of other enzyme classes including phosphatases
(Kumar et al., 2004) and glycosidases (Vocadlo and Bertozzi,
2004). A recent report demonstrated how ABPP can be used
to screen compound libraries against an entire target class
(Bachovchin et al., 2010). The authors first synthesized a probe
to capture 80% of all mammalian SHs, then screened 70 SHs
against 140 structurally diverse carbamates and assessed the
selectivity of hits using the very same approach. Importantly,
activity-based probes can be adapted for in situ and in vivo
labeling by introducing a bio-orthogonal chemical handle, such
as an alkyne. Probe-labeled enzymes can then be captured by
click chemistry conjugation to azide-containing reporter tags
(Wright and Cravatt, 2007; Speers et al., 2003; Speers and Cra-
vatt, 2004). The trifunctional probe design mentioned in the
Drug-Centric Chemoproteomic Profiling section has also been
applied to whole-enzyme classes by using a suitable pan-target
class selectivity group, e.g., for cAMP-binding proteins (Luo
et al., 2009), kinases (Fischer et al., 2010), and methyltrans-
ferases (Dalhoff et al., 2010).
Drug Mode of Action and Target Validation
Unbiased approaches to target deconvolution of hits and leads,
including the aforementioned proteomic strategies but also
genetic and bioinformatic techniques do not necessarily identify
well-annotated and -characterized target proteins. Hence,
a frequent initial challenge is to link these proteins to disease
biology and to elucidate the mode of action of how the drug
molecule generates the observed phenotype. One might argue
that this area of drug discovery is most closely related to basic
research because the focus is on the mechanistic understanding
of how modulation of a protein target can lead to an observed or
desired phenotype. A variety of proteomic experimental strate-
gies have been applied successfully in this area, both from
a basic research and a more targeted, drug discovery angle. It
should be noted that, in many cases, proof-of-concept studies
are done in model organisms with less-complex proteomes,
and the transfer to more complex mammalian systems is not
always straightforward. This is why in this section we will focus
on strategies that have either been applied successfully to
mammalian systems or where the complexity of the proteome
does not pose a conceptual challenge.
Protein-Protein Interactions
The generation of protein-protein interaction networks using
affinity proteomic approaches can help to characterize the func-
tional environment of the protein under investigation. Using the
‘‘guilt by association concept,’’ this often works even for proteins
without any prior functional annotation. In an ideal scenario,
placing a protein into an interaction network identifies a protein
directly as a player in the disease process under investigation
(Ruffner et al., 2007; Kruse et al., 2008; Oeljeklaus et al., 2009).78 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rTechnically, a protein of interest can be purified along with asso-
ciated interactors either using specific antibodies or one of
a variety of available tandem or single epitope tag systems (Ba-
uer and Kuster, 2003; Brizzard, 2008). Although immunoprecip-
itation (IP) allows for the purification of endogenous protein
complexes, tagged proteins offer greater experimental flexibility
(say to investigate wild-type versus mutant or enzymatically
active versus inactive forms of a protein). For both systems,
differential bait protein expression often combinedwith quantita-
tive mass spectrometry can be useful to discriminate between
bona fide interactors and high-abundance, low-affinity false
positives. This may be achieved for example by combining
protein knockdown by siRNA with IP (Selbach and Mann,
2006) or by using an inducible system for expression of the
bait protein (Medina et al., 2000). Alternatively, mock IPs using
isotype-matched IgG mixtures have been used successfully to
create background data sets for specificity assessment (Bant-
scheff et al., 2011). Moreover, for tagged proteins the knock-
down of the untagged endogenous protein by RNA interference
can help to increase enrichment efficiency of interactors that are
otherwise distributed between tagged and untagged versions of
the protein (Forler et al., 2003).
In the case of enzymes as targets, the experimental strategy
can be tailored to the identification of substrates. For example,
substrate-trapping mutants of phosphatases have been gener-
ated where the transient enzyme-substrate interaction is stabi-
lized by mutating residues involved in the catalytic mechanisms
(Flint et al., 1997). Combining this with an unbiased mass spec-
trometry readout has allowed the identification of substrates for
several phosphatases, including PTPN22 (Wu et al., 2006).
Another described example is the use of a tagged poly(ADP-
ribosyl) (PAR)-binding WWE domain and quantitative proteo-
mics. This experiment identified proteins that are PARsylated
by tankyrase, the target of the Wnt pathway inhibitor XAV939,
andwhose stability is regulatedby thePAR-recognizing E3 ligase
RNF146 (Zhang et al., 2011). Moreover, affinity matrices consist-
ing of small molecules and modified peptides have been used to
capture and characterize endogenous, biologically relevant
complexes. In the aforementioned study of BET inhibitors, an
in-depth characterization of functional BET protein complexes
was achieved by the combination of an immobilized BET family
inhibitor, acetylated histone H4 peptides (endogenous binding
partners of the BET family), and BET IP (Dawson et al., 2011).
In addition, protein-protein interaction studies can be used to
shed light on mechanisms other than direct inhibition or activa-
tion by which a drug can modulate target activity. Differential
protein complexes observed with and without compound treat-
ment, either on cell, in lysate or during the purification procedure,
allow the identification of compound-sensitive protein-protein
interactions. Using tagged subunits of the SIN3A HDAC
complex, Smith and colleagues found that SAHA, the first
FDA-approved HDAC inhibitor for the treatment of cancer,
causes dissociation of the ING2 subunit from this complex.
Absence of ING2 leads to loss of binding of the SIN3A complex
to the p21 promoter and, thus, directly contributes to the growth
inhibitory effect of SAHA (Smith et al., 2010). Another example is
the identification of the interaction of tagged cAMP-dependent
protein kinase (PKA) subunit Cb1 and CAP1, which was shown
to be sensitive to an ATP-competitive PKA inhibitor (Erlbruchights reserved
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tionmaps, e.g., of complete disease-related signaling pathways,
can also enable the identification of druggable components that
might even have a more favorable target profile than others. An
early focused example was the interaction mapping around 32
members of the pro-inflammatory TNF-a-induced NKkB
pathway. This study resulted in 80 novel protein interactions,
and genetic validation of a modulatory role in TNF-a signaling
could be shown for 10 of these proteins (Bouwmeester et al.,
2004). More recently, an interesting study has been published
by Moulick et al. in which the authors identified the selective
binding of the HSP90 inhibitor PU-H71 to cancer-specific onco-
protein-HSP90 complexes using an immobilized PU-H71 matrix
(Moulick et al., 2011). Malovannaya et al. recently published
a massive global IP study that characterized the endogenous
human complexome and its organization (Malovannaya et al.,
2011). The authors amassed data from >3,000 affinity purifica-
tions identifying >10,000 proteins, which may turn out to be
a valuable future resource for drug discovery strategies targeting
protein complexes.
Global Proteomic Profiling
On a global proteomic scale, advances in mass spectrometry
instrumentation, sample preparation, and data analysis are
now allowing for the identification of some 5–10,000 proteins in
a single-cell line (Beck et al., 2011; Nagaraj et al., 2011). Although
still fairly time consuming (1–10 days per experiment), global pro-
teome profiling is reaching a level of depth at which it becomes
a viable complement to gene expression profiling for mode of
action studies. Monitoring (co)regulation of proteins implicated
in a particular cellular process upon drug treatment can function-
ally link a drug and/or target to direct or indirect induction or
inhibition of these mechanisms. This approach should prove
particularly useful when investigating drugs that directly affect
the stability of proteins such as inhibitors of proteases or other
enzymes involved in proteolytic pathways, such as the ubiquitin
system.
Proteomic Profiling of PTMs
Proteomic approaches are becoming an important tool to char-
acterize the mode of action of compounds modulating enzymes
involved in PTM of substrate proteins such as phosphorylation,
acetylation, and ubiquitination. For example, differential phos-
phoproteomic analyses using selective small molecule inhibitors
of particular kinases have been used to identify substrates in
human cell lines and characterize the effect of inhibition on
signaling events. Examples include the MAPK inhibitors U0126
and SB202190, the clinical BCR-ABL inhibitor Dasatinib (Pan
et al., 2009), and, more recently, inhibitors of Aurora and Polo-
like kinases (Kettenbach et al., 2011). Because such global
studies do not distinguish between changes in phosphorylation
status of direct substrates and downstream members of the
signaling cascade, extensive bioinformatic analysis and in vitro
validation are required. In contrast the chemogenetic kinase
substrate-trapping approach originally developed by the Shokat
group (Shah et al., 1997) allows for direct and unequivocal iden-
tification of kinase substrates. The system essentially uses
a genetically engineered kinase ATP-binding pocket that can
bind an unnatural bulky ATP analog (which cannot be bound
by the wild-type kinase) and transfer its phosphate group to
substrate proteins. Using thio-ATP followed by a covalentChemistry & Biolcapture/release enrichment step and identification of modified
peptides by mass spectrometry, this strategy has also been
used successfully for the characterization of CDK1 and CDK2
targets in human cells (Blethrow et al., 2008; Chi et al., 2008).
Another current focus of drug discovery efforts is epigenetic
targets that modulate the posttranslational modification state
of histones. Quantitative proteomics has been used successfully
in many cases to study the effect of small molecule inhibitors by
monitoring protein acetylation and methylation. In an early
example, Garcia et al. described the quantitative effects of the
HDAC inhibitor trichostatin A on the histone modification state
in a murine model of systemic lupus erythematosus (Garcia
et al., 2005). Lee and colleagues used label-free mass spectrom-
etry to quantify the effect of HDAC inhibitors of varying degrees
of selectivity on histone acetylation (Lee et al., 2008). More
recently, proteomic approaches have been used to study the
effect of inhibition of the histone demethylase JMJD2A by pyri-
dine-2,4-dicarboxylic acid derivatives (Mackeen et al., 2010) as
well as the histonemethyltransferases G9A andGLP by the small
molecule inhibitor UNC0638 (Vedadi et al., 2011). Finally, the
recent development of antibodies recognizing the diglycyl modi-
fication of lysine side chains resulting from trypsinolysis of ubiq-
uitin conjugates allows monitoring the effect of inhibitors of
components of the ubiquitin/proteasome system. These long-
awaited reagents have been used in two recent studies that
describe quantitative changes in the ubiquitin-modified pro-
teome upon treatment with the proteasome inhibitors MG132
and Bortezomib (Wagner et al., 2011; Kim et al., 2011). These
antibodies will also turn out to be useful for substrate identifica-
tion for other, upstream, targets in the ubiquitin system. Obvi-
ously, application of the proteomic strategies described above
is not restricted to the identification of the mode of action of
a drug but can also be applied to the identification of cellular
mechanisms that result in drug resistance. Upregulation of
compensatory pathways can be detected by changes in protein
abundance or in proxies of pathway activity such as its phos-
phorylation state. In a recent example, Gioia et al. used quantita-
tive phosphoproteomics to identify an oncogenic signaling
cascade mediated by LYN and SYK that can bypass BCR-ABL
in chronic lymphoid myeloma cells, thus conferring resistance
to chemotherapy targeting BCR-ABL (Gioia et al., 2011).
Biomarker Discovery and Preclinical Drug Discovery
The area of proteomic biomarker discovery and verification has
acquired a lot of attention and spurred a great deal of research
activity during recent years (reviewed in Brennan et al., 2010; Di-
amandis, 2004; Makawita and Diamandis, 2010; Rifai et al.,
2006; Schiess et al., 2009; Zolg and Langen, 2004; Colburn,
2003; Sinha et al., 2007). Within the scope of this review, we
must, however, confine ourselves to presenting just a few
aspects of the identification of pharmacodynamic biomarkers
using proteomics. Pharmacodynamics (PD) can pragmatically
be summarized as the study of what a drug does to the body
(or a relevant model system for that matter) and in our context,
therefore, mainly relates to questions about drug efficacy, drug
toxicity, and the therapeutic index of a drug. The application of
proteomics to the identification of such PD biomarkers can
take many forms but ideally closely follows and complements
the panel of in vitro and in vivo assays established for a particularogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 79
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biomarker should be able tomonitor the (successful) intervention
in a disease-relevant process or highlight toxic effects in
response to the treatment.
Proteomic Biomarkers for Evaluating Drug Efficacy
In 2005, Fishman and Porter proposed ‘‘a new grammar for drug
discovery’’ (Fishman and Porter, 2005) that argued that ‘‘to
realize the potential of the genome for identifying candidate
drugs we must move beyond individual genes and proteins.
The signaling pathways in cells provide the right level for such
analyses.’’ Much about what was said about pathways and the
identification of drug targets in this publication also applies to
the identification of molecular protein biomarkers that aim to
measure the efficacy of a drug. Because many drugs target
enzymes, a viable proteomic biomarker approach is to identify
substrates that are directly or indirectly affected by the treat-
ment. This in fact is often tightly connected to MoA studies of
a drug (see previous section). Therefore, the identification of
a (mechanistic) biomarker of drug efficacy can be achieved for
example via monitoring the levels of PTMs such as protein phos-
phorylation for kinase substrates, protein acetylation for moni-
toring (de)acetylase activity, or the identification of protein
fragments indicative of protease activity. The power of mass
spectrometry-based proteomics here is its ability to discover
these modifications at a large scale (hundreds to thousands)
and to monitor their response to drug treatment or other system
perturbations quantitatively (Choudhary et al., 2009; Gevaert
et al., 2003; Olsen et al., 2006). This is an important conceptual
and technical advantage over traditional antibody-based
methods such as PTM-specific western blotting. Immunological
methods are of course very valuable in the verification phase and
for monitoring large numbers of samples, but the appropriate
reagents can also often be difficult and time consuming to
generate. An alternative to using the output of an enzymatic
activity as a molecular PD biomarker as described above is to
monitor global protein levels as a surrogate for the effect of the
applied treatment. This is for example relevant for therapeutic
strategies targeting the proteasome (Kraus et al., 2007) or the
protein-folding machinery (Schumacher et al., 2007) but can
also apply to cases where the pharmacological loss of function
of one protein causes the cell to express increased levels of
another protein with redundant function (Guo et al., 2008).
Proteomic Biomarkers for Evaluating Drug Toxicity
A large proportion of failures in drug discovery and development
projects are not due to limited efficacy but result from toxicity.
This is also true for drugs in clinical trials, and indeed, many
approved drugs are later withdrawn from the market because
of issues of toxicity. Drug toxicity can of course have many
reasons, but for the sake of argument, these can broadly be
divided into the two categories of on-target toxicity and off-
target toxicity. On-target toxicity refers to the situation in which
a drug targets the desired protein, but the induced loss or gain
of function exhibits undesirable biological effects limiting the
usefulness of the treatment. Well-known examples for this cate-
gory include drugs targeting the p38MAP kinase in inflammatory
diseases (Hammaker and Firestein, 2010). Conversely, off-target
toxicity refers to an unintended interaction of a drug with one or
more proteins that may lead to adverse effects on the function of
organs such as the liver, kidney, and others. The prime example80 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rfor this category is the inhibition of drug-metabolizing enzymes
of the P450 family, but also for example kinase inhibitors with
limited selectivity can fall into this class. Proteomic studies on
drug selectivity and MoA can, therefore, often highlight potential
toxicity issues early on and, thus, provide a valuable source for
appropriate molecular (toxicity) biomarkers (see also the above
sections) (Amacher, 2010; Kennedy, 2002). Liver toxicity is
a particularly problematic issue and is indeed frequently
observed. Here, global proteome profiling of human hepatocytes
or rodent livers exposed to a drug can be employed to obtain an
appreciation of the effects the treatment may impose. Proteins
identified to change in abundance in response to drugs may
thus be useful surrogate PD biomarkers (Yamanaka et al.,
2007; Ortiz et al., 2010; Ge et al., 2007). Much of the aforemen-
tioned PD biomarker discovery work is carried out in model cell
lines. It is, however, important to translate such findings into rele-
vant animal models of disease and, eventually, the human situa-
tion. Samples from drug-treated rodents for proteomic analysis
can often quite easily be obtained, but translation to humans is
often complicated by a number of points. First, the molecular
mechanism by which a drug works may not be the same in
both species (which would indeed question the validity of the
animalmodel). Second, the pharmacokinetics andPDof a partic-
ular drug treatment are clearly different between cellular model
systems, whole organisms and species, so it may not be very
clear how an effective dose determined from work in cell lines
can be extrapolated to the animal situation. Third, the disease
often only affects a small number of cells in the rodent or human
subject, and these cells are surrounded by stroma or other cell
types. Direct proteomic analysis on these systems by mass
spectrometry can be difficult because the biomarker signal is
diluted out by the presence of the other tissue components.
Therefore, molecular monitoring of treatment efficacy in animal
models (and humans) mostly relies onmethodswith good spatial
resolution such as immunohistochemistry. In this regard the
Human Protein Atlas project (Uhlen et al., 2010) may become
a valuable resource of reagents and information for the clinical
validation of biomarkers identified by proteomics because the
project has already generated antibodies to >10,000 human
proteins along with immunohistochemistry profiles in several
disease tissue types. It should be noted though that this panel
of antibody reagents is not yet fully validated in terms of protein
detection specificity.
Conclusion and Outlook
In light of thewide range of successful applications of proteomics
to small molecule drug discovery described in this review, one
may ask the general question what the overall role of proteomics
in drug discovery is. Quite obviously, proteomics (and genomics
for that matter) constitutes a rather small piece in the very
complex drug discovery puzzle, and proteomic information may
sometimes be decisive and sometimes not. From a bibliographic
analysis, one notes that 1.4% of all publications in PubMed
mentioning drug discovery in addressable fields of the database
(92,000at the timeofwriting) alsomentionproteomics (2.8% for
genomics). Interestingly, of the 1,300 PubMed entries on ‘‘Pro-
teomics and Drug Discovery,’’ more than half are classified as
reviews, and the overall number of publications and the ratio of
reviews to all publications are only changing slowly (Figure 3).ights reserved
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Figure 3. Bibliographical Analysis of Proteomics in Drug Discovery
Searching PubMed in all addressable fields for ‘‘proteomics and drug
discovery’’ reveals a slow but steady increase in the number of publications
over the past 12 years, which is broadly in line with the overall growth of
publications in PubMed. Interestingly, the gap between reviews and all
publications on the subject has only begun to widen recently, indicating that
proteomics is beginning to make more significant contributions to the field.
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aforementioned fact that proteomics actually constitutes only
a small aspect of drug discovery research. A second reason
that is muchmore relevant for drug discovery than for other basic
science researchmaybe that intellectual property considerations
often preclude the disclosure of results. Therefore, amere survey
of the published literature may not be a fair representation of the
actual situation.Webelieve that after an early firstwave at the end
of the last century, proteomics in drug discovery is now experi-
encing a second and much more significant wave of focused
activities that will undoubtedly have increasing impact on the
way we discover and assess drugs. In particular for the rapidly
growing area of chemogenetics and the renaissance of pheno-
typic screening, proteomics is among the most promising
approaches to target deconvolution and mechanism-based
biomarker discovery. An unbiased assessment of the full spec-
trum of drug-target interactions and their molecular mode of
action is now technically within reach. This should not only lead
to a better understanding of what a small molecule actually
does to a biological system but also to a better appreciation of
how this information may be exploited therapeutically.
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